Wissenschaftliche Literaturquellen

  1. AWMF: Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, Langversion 5.1, 2019, AWMF Registernummer: 043/022OL., 2019. https://www.awmf.org/leitlinien/detail/ll/043-022OL.html
  1. Bazinet, A., Zorn, K. C., Taussky, D. et al.: Favorable preservation of erectile function after prostate brachytherapy for localized prostate cancer. Brachytherapy, 2019. http://www.ncbi.nlm.nih.gov/pubmed/31837989
  1. Blanchard, P., Davis, J. W., Frank, S. J. et al.: Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohort. BJU Int, 121: 540, 2018. http://www.ncbi.nlm.nih.gov/pubmed/28941030
  1. Cox, J. D., Stetz, J., Pajak, T. F.: Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys, 31: 1341, 1995. https://www.ncbi.nlm.nih.gov/pubmed/7713792
  1. Cozzi, G., Musi, G., Bianchi, R. et al.: Meta-analysis of studies comparing oncologic outcomes of radical prostatectomy and brachytherapy for localized prostate cancer. Ther Adv Urol, 9: 241, 2017. http://www.ncbi.nlm.nih.gov/pubmed/29662542
  1. Davis, B. J., Horwitz, E. M., Lee, W. R. et al.: American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy, 11: 6, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22265434
  1. Fisher, C. M., Troncoso, P., Swanson, D. A. et al.: Knife or needles? A cohort analysis of outcomes after radical prostatectomy or brachytherapy for men with low- or intermediate-risk adenocarcinoma of the prostate. Brachytherapy, 11: 429, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22727472
  1. Giberti, C., Chiono, L., Gallo, F. et al.: Radical retropubic prostatectomy versus brachytherapy for low-risk prostatic cancer: a prospective study. World J Urol, 27: 607, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19455340
  1. Goy, B. W., Burchette, R., Soper, M. S. et al.: Ten-Year Treatment Outcomes of Radical Prostatectomy Vs External Beam Radiation Therapy Vs Brachytherapy for 1503 Patients With Intermediate-risk Prostate Cancer. Urology, 136: 180, 2020. http://www.ncbi.nlm.nih.gov/pubmed/31704459
  1. Grimm, P., Billiet, I., Bostwick, D. et al.: Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int, 109 Suppl 1: 22, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22239226
  1. Hoffman, K. E., Penson, D. F., Zhao, Z. et al.: Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer. JAMA, 323: 149, 2020. http://www.ncbi.nlm.nih.gov/pubmed/31935027
  1. Hoskin, P. J., Colombo, A., Henry, A. et al.: GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: an update. Radiother Oncol, 107: 325, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23773409
  1. Hunter, G. K., Reddy, C. A., Klein, E. A. et al.: Long-term (10-year) gastrointestinal and genitourinary toxicity after treatment with external beam radiotherapy, radical prostatectomy, or brachytherapy for prostate cancer. Prostate Cancer, 2012: 853487, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22577562
  1. Kalapara, A. A., Verbeek, J. F. M., Nieboer, D. et al.: Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance Initiative. Eur Urol Oncol, 3: 80, 2020. http://www.ncbi.nlm.nih.gov/pubmed/31564531
  1. Miwa, S., Mizokami, A., Konaka, H. et al.: Prospective longitudinal comparative study of health-related quality of life and treatment satisfaction in patients treated with hormone therapy, radical retropubic prostatectomy, and high or low dose rate brachytherapy for prostate cancer. Prostate Int, 1: 117, 2013. http://www.ncbi.nlm.nih.gov/pubmed/24223413
  1. Niehaus, A., Merrick, G. S., Butler, W. M. et al.: The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy. Int J Radiat Oncol Biol Phys, 64: 136, 2006. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16198062
  1. Ohashi, T., Yorozu, A., Saito, S. et al.: Urinary and Rectal Toxicity Profiles After Permanent Iodine-125 Implant Brachytherapy in Japanese Men: Nationwide J-POPS Multi-institutional Prospective Cohort Study. Int J Radiat Oncol Biol Phys, 93: 141, 2015. http://www.ncbi.nlm.nih.gov/pubmed/26279031
  1. Onishi, K., Tanaka, N., Miyake, M. et al.: Changes in lower urinary tract symptoms after iodine-125 brachytherapy for prostate cancer. Clin Transl Radiat Oncol, 14: 51, 2019. http://www.ncbi.nlm.nih.gov/pubmed/30547097
  1. Pardo, Y., Guedea, F., Aguilo, F. et al.: Quality-of-life impact of primary treatments for localized prostate cancer in patients without hormonal treatment. J Clin Oncol, 28: 4687, 2010. http://www.ncbi.nlm.nih.gov/pubmed/20921463
  1. Peinemann, F., Grouven, U., Bartel, C. et al.: Permanent interstitial low-dose-rate brachytherapy for patients with localised prostate cancer: a systematic review of randomised and nonrandomised controlled clinical trials. Eur Urol, 60: 881, 2011. http://www.ncbi.nlm.nih.gov/pubmed/21763066
  1. Salembier, C., Lavagnini, P., Nickers, P. et al.: Tumour and target volumes in permanent prostate brachytherapy: a supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy. Radiother Oncol, 83: 3, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17321620
  1. Schouten, B. W., Bohnen, A. M., Groeneveld, F. P. et al.: Erectile dysfunction in the community: trends over time in incidence, prevalence, GP consultation and medication use–the Krimpen study: trends in ED. J Sex Med, 7: 2547, 2010. http://www.ncbi.nlm.nih.gov/pubmed/20497307
  1. Smith, D. P., King, M. T., Egger, S. et al.: Quality of life three years after diagnosis of localised prostate cancer: population based cohort study. BMJ, 339: b4817, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19945997
  1. Stock, R. G., Kao, J., Stone, N. N.: Penile erectile function after permanent radioactive seed implantation for treatment of prostate cancer. J Urol, 165: 436, 2001. http://www.ncbi.nlm.nih.gov/pubmed/11176391
  1. Stone, N. N., Stock, R. G.: Prospective assessment of patient-reported long-term urinary morbidity and associated quality of life changes after 125I prostate brachytherapy. Brachytherapy, 2: 32, 2003. http://www.ncbi.nlm.nih.gov/pubmed/15062161
  1. Stone, N. N., Stock, R. G.: Long-term urinary, sexual, and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5 years. Urology, 69: 338, 2007. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17320674
  1. Sureda, A., Fumado, L., Ferrer, M. et al.: Health-related quality of life in men with prostate cancer undergoing active surveillance versus radical prostatectomy, external-beam radiotherapy, prostate brachytherapy and reference population: a cross-sectional study. Health Qual Life Outcomes, 17: 11, 2019. http://www.ncbi.nlm.nih.gov/pubmed/30642340
  1. Tanaka, N., Asakawa, I., Hasegawa, M. et al.: Low-dose-rate brachytherapy for prostate cancer: A 15-year experience in Japan. Int J Urol, 27: 17, 2020. http://www.ncbi.nlm.nih.gov/pubmed/31549770
  1. Tom, M. C., Reddy, C. A., Smile, T. D. et al.: Validation of the NCCN prostate cancer favorable- and unfavorable-intermediate risk groups among men treated with I-125 low dose rate brachytherapy monotherapy. Brachytherapy, 19: 43, 2020. http://www.ncbi.nlm.nih.gov/pubmed/31813740
  1. Viktorin-Baier, P., Putora, P. M., Schmid, H. P. et al.: Long-term oncological and functional follow-up in low-dose-rate brachytherapy for prostate cancer: results from the prospective nationwide Swiss registry. BJU Int, 2020. http://www.ncbi.nlm.nih.gov/pubmed/31965694
  1. Vuolukka, K., Auvinen, P., Palmgren, J. E. et al.: Long-term efficacy and urological toxicity of low-dose-rate brachytherapy (LDR-BT) as monotherapy in localized prostate cancer. Brachytherapy, 18: 583, 2019. http://www.ncbi.nlm.nih.gov/pubmed/31227400
  1. Winoker, J. S., Say, R. K., Mehrazin, R. et al.: Permanent prostate brachytherapy is safe in men with severe baseline lower urinary tract symptoms. Brachytherapy, 18: 332, 2019. http://www.ncbi.nlm.nih.gov/pubmed/30890317
  1. Yamada, Y., Rogers, L., Demanes, D. J. et al.: American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy. Brachytherapy, 11: 20, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22265435
  1. Zhou, Z., Yan, W., Zhou, Y. et al.: (125)I low-dose-rate prostate brachytherapy and radical prostatectomy in patients with prostate cancer. Oncol Lett, 18: 72, 2019. http://www.ncbi.nlm.nih.gov/pubmed/31289474